Is Krill Oil Triglycerides Randomized Trial safe?

Updated July 2026

Quick Answer

Krill Oil Triglycerides Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: BACKGROUND: Hypertriglyceridemia is a modifiable risk factor for cardiovascular disease, and while omega-3 fatty acids (omega-3 FAs) are known to lower triglyceride (TG) concentrations, their effectiveness is influenced by formulation and bioavailability.

Key Takeaways

  • 01BACKGROUND: Hypertriglyceridemia is a modifiable risk factor for cardiovascular disease, and while omega-3 fatty acids (omega-3 FAs) are known to lower triglyceride (TG) concentrations, their effectiveness is influenced by formulation and bioavailability. [Urina-Triana M (2026)]
  • 02Phospholipid-bound (PL) omega-3 FAs—such as those found in krill oil—demonstrate superior intestinal absorption and membrane integration compared with TG- and ethyl ester omega-3 FAs based forms. [Urina-Triana M (2026)]
  • 03Mean TG levels decreased slightly in the PL group (-9.1 mg/dL) and increased in the standard group (+ 15.2 mg/dL), with no statistically significant difference between-groups (p = 0.416). [Urina-Triana M (2026)]
  • 041 2 1 2 3 4 The age-related loss of muscle mass and strength, known as sarcopenia, is associated with reduced quality of life, greater risk of falls, and increased healthcare costs, estimated at £2.5 billion annually in the UK [,]. [Hayman Oliver (2026)]
The current Migaku evidence database contains 2 reusable source documents for Krill Oil Triglycerides Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - BACKGROUND: Hypertriglyceridemia is a modifiable risk factor for cardiovascular disease, and while omega-3 fatty acids (omega-3 FAs) are known to lower triglyceride (TG) concentrations, their effectiveness is influenced by formulation and bioavailability. [Urina-Triana M (2026); evidence level 2] - Phospholipid-bound (PL) omega-3 FAs—such as those found in krill oil—demonstrate superior intestinal absorption and membrane integration compared with TG- and ethyl ester omega-3 FAs based forms. [Urina-Triana M (2026); evidence level 2] - Mean TG levels decreased slightly in the PL group (-9.1 mg/dL) and increased in the standard group (+ 15.2 mg/dL), with no statistically significant difference between-groups (p = 0.416). [Urina-Triana M (2026); evidence level 2] - 1 2 1 2 3 4 The age-related loss of muscle mass and strength, known as sarcopenia, is associated with reduced quality of life, greater risk of falls, and increased healthcare costs, estimated at £2.5 billion annually in the UK [,]. [Hayman Oliver (2026); evidence level 2] - 5 6 7 8 9 10 11 Building on epidemiological [,], cell culture, and animal data [,], human research has demonstrated that 8 weeks of long-chain n-3 polyunsaturated fatty acid (LCn-3 PUFA) supplementation (fish oil, 4 g/day) increased muscle protein synthesis (MPS) during a hyperaminoacidaemic-hyperinsulinaemic clamp in older adults []. [Hayman Oliver (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Efficacy of phospholipid-bound omega-3 versus standard omega-3 in patients with hypertriglyceridemia: a randomized clinical trial.
  2. Do the effects of krill oil supplementation on skeletal muscle function and size in older adults differ by sex, age or BMI: A secondary analysis of a randomised controlled trial